MYX 3.79% $4.65 mayne pharma group limited

Business Outlook and Priorities for FY24, page-2

  1. 900 Posts.
    lightbulb Created with Sketch. 51
    NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days agoMore than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
(20min delay)
Last
$4.65
Change
0.170(3.79%)
Mkt cap ! $395.5M
Open High Low Value Volume
$4.50 $4.68 $4.47 $1.532M 331.3K

Buyers (Bids)

No. Vol. Price($)
1 206 $4.63
 

Sellers (Offers)

Price($) Vol. No.
$4.65 262 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$4.61
  Change
0.170 ( 2.41 %)
Open High Low Volume
$4.47 $4.68 $4.47 64875
Last updated 15.59pm 14/06/2024 ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.